PFE logo

Pfizer Inc. Stock Price

NYSE:PFE Community·US$143.5b Market Cap
  • 4 Narratives written by author
  • 1 Comments on narratives written by author
  • 893 Fair Values set on narratives written by author

PFE Share Price Performance

US$24.78
-4.38 (-15.02%)
30.7% undervalued intrinsic discount
US$35.77
Fair Value
US$24.78
-4.38 (-15.02%)
34.7% undervalued intrinsic discount
US$37.92
Fair Value
Price US$24.78
AnalystHighTarget US$37.92
Francisco US$30.62
AnalystConsensusTarget US$28.77

PFE Community Narratives

AnalystHighTarget·
Fair Value US$35.77 28.2% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Unlock New Opportunities

2users have liked this narrative
0users have commented on this narrative
28users have followed this narrative
Francisco·
Fair Value US$30.62 16.1% undervalued intrinsic discount

Pfizer's Future Depends on Oncology Growth, New Products and operational efficiency

1users have liked this narrative
0users have commented on this narrative
29users have followed this narrative
AnalystConsensusTarget·
Fair Value US$28.86 11.0% undervalued intrinsic discount

Expanding Oncology Pipelines And Emerging Markets Will Unlock Future Success

5users have liked this narrative
1users have commented on this narrative
444users have followed this narrative

Recent PFE News & Updates

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

Pfizer Inc. Key Details

US$63.8b

Revenue

US$16.7b

Cost of Revenue

US$47.1b

Gross Profit

US$36.4b

Other Expenses

US$10.7b

Earnings

Last Reported Earnings
Jun 29, 2025
Next Reporting Earnings
Nov 04, 2025
Earnings per share (EPS)
1.89
Gross Margin
73.82%
Net Profit Margin
16.81%
Debt/Equity Ratio
69.7%

Pfizer Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

6 star dividend payer and undervalued.

2 Risks
4 Rewards

About PFE

Founded
1849
Employees
81000
CEO
Albert Bourla
WebsiteView website
www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a loss of 2.5% in the Information Technology sector. In the last year, the market is actually up 13%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›